53987-60-3

Usage

Uses

Used in Organic Synthesis:
Isoquinoline,1,3-dibromois employed as a building block in organic synthesis for the creation of more complex organic molecules. Its unique structural properties make it a valuable component in the synthesis of various organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Isoquinoline,1,3-dibromois used as a key intermediate in the development of new pharmaceuticals. Its structural features contribute to the design and synthesis of potential drug candidates.
Used in Pharmaceutical Industry:
Isoquinoline,1,3-dibromois utilized as a precursor in the pharmaceutical industry for the synthesis of drugs with specific therapeutic properties. Its unique bromine-substituted structure may offer advantages in the development of novel medications.
Used in Agrochemical Industry:
Isoquinoline,1,3-dibromomay also find applications in the agrochemical industry, where it could be used as a starting material for the synthesis of agrochemicals with specific pesticidal or herbicidal activities. Its structural attributes could be leveraged to create effective compounds for agricultural use.

Upstream product

• 102879-33-4 5,6,7,8-tetrahydroisoquinolin-3-ol 
• 89-51-0 Homophthalic acid 
• 4456-77-3 4H-isoquinolin-1,3-dione 

Downstream Products

• 34784-02-6 3-bromoisoquinoline 
• 851542-17-1 3-diphenylphosphinoisoquinolone 
• 1613435-47-4 1-methoxy-5-nitro-3-(2-trifluoromethylphenyl)isoquinoline 
• 1613435-50-9 1-methoxy-5-nitro-3-(2-phenylethynyl)isoquinoline 
• 1613435-48-5 1-methoxy-5-nitro-3-(3-trifluoromethylphenyl)isoquinoline 
• 1613435-44-1 1-methoxy-5-nitro-3-(4-trifluoromethylphenyl)isoquinoline 
• 1613435-43-0 3-(4-fluorophenyl)-1-methoxy-5-nitroisoquinoline 
• 1613435-40-7 3-(2-chlorophenyl)-1-methoxy-5-nitroisoquinoline 
• 1613435-41-8 3-(3-chlorophenyl)-1-methoxy-5-nitroisoquinoline 
• 1613435-42-9 3-(2,6-dichlorophenyl)-1-methoxy-5-nitroisoquinoline 
• 1613435-45-2 3-(3-cyanophenyl)-1-methoxy-5-nitroisoquinoline 
• 1613435-46-3 3-(4-cyanophenyl)-1-methoxy-5-nitroisoquinoline 
• 1613435-30-5 5-amino-1-methoxy-3-(2-trifluoromethylphenyl)isoquinoline 
• 1613435-32-7 5-amino-1-methoxy-3-(3-trifluoromethylphenyl)isoquinoline 

Relevant academic research and scientific papers

Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro

Tankyrases-1 and -2 (TNKS-1 and TNKS-2) have three cellular roles which make them important targets in cancer. Using NAD+ as a substrate, they poly(ADP-ribosyl)ate TRF1 (regulating lengths of telomeres), NuMA (facilitating mitosis) and axin (in wnt/β-catenin signalling). Using molecular modelling and the structure of the weak inhibitor 5-aminoiso quinolin-1-one, 3-aryl-5-substituted-isoquinolin-1-ones were designed as inhibitors to explore the structure-activity relationships (SARs) for binding and to define the shape of a hydrophobic cavity in the active site. 5-Amino-3-arylisoquinolinones were synthesised by Suzuki-Miyaura coupling of arylboronic acids to 3-bromo-1-methoxy-5-nitro-isoquinoline, reduction and O-demethylation. 3-Aryl-5-methylisoquinolin-1-ones, 3-aryl-5-fluoroisoquinolin-1-ones and 3-aryl-5-methoxyisoquinolin-1-ones were accessed by deprotonation of 3-substituted-N,N,2-trimethylbenzamides and quench with an appropriate benzonitrile. SAR around the isoquinolinone core showed that aryl was required at the 3-position, optimally with a para-substituent. Small meta-substituents were tolerated but groups in the ortho-positions reduced or abolished activity. This was not due to lack of coplanarity of the rings, as shown by the potency of 4,5-dimethyl-3-phenylisoquinolin-1-one. Methyl and methoxy were optimal at the 5-position. SAR was rationalised by modelling and by crystal structures of examples with TNKS-2. The 3-aryl unit was located in a large hydrophobic cavity and the para-substituents projected into a tunnel leading to the exterior. Potency against TNKS-1 paralleled potency against TNKS-2. Most inhibitors were highly selective for TNKSs over PARP-1 and PARP-2. A range of highly potent and selective inhibitors is now available for cellular studies.